241 related articles for article (PubMed ID: 26375674)
41. Use of pneumatic nebulization and laser ablation-inductively coupled plasma-mass spectrometry to study the distribution and bioavailability of an intraperitoneally administered Pt-containing chemotherapeutic drug.
Gholap D; Verhulst J; Ceelen W; Vanhaecke F
Anal Bioanal Chem; 2012 Feb; 402(6):2121-9. PubMed ID: 22252654
[TBL] [Abstract][Full Text] [Related]
42. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways.
Greening DW; Lee ST; Ji H; Simpson RJ; Rigopoulos A; Murone C; Fang C; Gong S; O'Keefe G; Scott AM
Oncotarget; 2015 Nov; 6(35):38166-80. PubMed ID: 26517691
[TBL] [Abstract][Full Text] [Related]
43. Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery.
Pérez-Ruixo C; Valenzuela B; Peris JE; Bretcha-Boix P; Escudero-Ortiz V; Farré-Alegre J; Pérez-Ruixo JJ
Cancer Chemother Pharmacol; 2013 Mar; 71(3):693-704. PubMed ID: 23274396
[TBL] [Abstract][Full Text] [Related]
44. Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction.
Klaver YL; Chua TC; Verwaal VJ; de Hingh IH; Morris DL
J Surg Oncol; 2013 May; 107(6):585-90. PubMed ID: 23280508
[TBL] [Abstract][Full Text] [Related]
45. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin.
Elias D; Mariani A; Cloutier AS; Blot F; Goéré D; Dumont F; Honoré C; Billard V; Dartigues P; Ducreux M
Eur J Surg Oncol; 2014 Nov; 40(11):1467-73. PubMed ID: 25086990
[TBL] [Abstract][Full Text] [Related]
46. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
[TBL] [Abstract][Full Text] [Related]
47. Survival prognostic factors in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy: a single institution experience.
Nikolic S; Dzodic R; Zegarac M; Djurisic I; Gavrilovic D; Vojinovic V; Kocic M; Santrac N; Radlovic P; Radosavljevic D; Pupic G; Martinovic A
J BUON; 2014; 19(1):66-74. PubMed ID: 24659645
[TBL] [Abstract][Full Text] [Related]
48. [Cytoreductive surgery and intraperitoneal hyperthermic-antiblastic therapy (HAPP) in peritoneal carcinomatosis].
Vaira M; Scuderi S; Costamagna D; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Chir; 2002 Oct; 57(5):597-605. PubMed ID: 12370661
[TBL] [Abstract][Full Text] [Related]
49. Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.
Cohen MS; Al-Kasspooles MF; Williamson SK; Henry D; Broward M; Roby KF
Ann Surg Oncol; 2010 Jan; 17(1):296-303. PubMed ID: 19707832
[TBL] [Abstract][Full Text] [Related]
50. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
[TBL] [Abstract][Full Text] [Related]
51. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.
Glehen O; Kwiatkowski F; Sugarbaker PH; Elias D; Levine EA; De Simone M; Barone R; Yonemura Y; Cavaliere F; Quenet F; Gutman M; Tentes AA; Lorimier G; Bernard JL; Bereder JM; Porcheron J; Gomez-Portilla A; Shen P; Deraco M; Rat P
J Clin Oncol; 2004 Aug; 22(16):3284-92. PubMed ID: 15310771
[TBL] [Abstract][Full Text] [Related]
52. The synergistic effect of recombinant human endostatin (YH-16) combined with oxaliplatin on human colorectal carcinoma.
Zhang DW; Li HL; Yao Q; Yang WL; Wang HL; Zhai DX; Zhou ZH
J Int Med Res; 2010; 38(1):111-26. PubMed ID: 20233520
[TBL] [Abstract][Full Text] [Related]
53. Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin.
Zhao S; Cai J; Bian H; Gui L; Zhao F
Cancer Invest; 2009 Jul; 27(6):636-40. PubMed ID: 19387877
[TBL] [Abstract][Full Text] [Related]
54. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
Verwaal VJ; van Ruth S; de Bree E; van Sloothen GW; van Tinteren H; Boot H; Zoetmulder FA
J Clin Oncol; 2003 Oct; 21(20):3737-43. PubMed ID: 14551293
[TBL] [Abstract][Full Text] [Related]
55. Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model.
Piché N; Leblond FA; Sidéris L; Pichette V; Drolet P; Fortier LP; Mitchell A; Dubé P
Ann Surg; 2011 Jul; 254(1):138-44. PubMed ID: 21494122
[TBL] [Abstract][Full Text] [Related]
56. Targeting of cancer‑associated fibroblasts enhances the efficacy of cancer chemotherapy by regulating the tumor microenvironment.
Li M; Li M; Yin T; Shi H; Wen Y; Zhang B; Chen M; Xu G; Ren K; Wei Y
Mol Med Rep; 2016 Mar; 13(3):2476-84. PubMed ID: 26846566
[TBL] [Abstract][Full Text] [Related]
57. Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer.
Grapsa D; Syrigos K; Saif MW
Expert Rev Anticancer Ther; 2015; 15(11):1267-81. PubMed ID: 26506906
[TBL] [Abstract][Full Text] [Related]
58. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
Terme M; Pernot S; Marcheteau E; Sandoval F; Benhamouda N; Colussi O; Dubreuil O; Carpentier AF; Tartour E; Taieb J
Cancer Res; 2013 Jan; 73(2):539-49. PubMed ID: 23108136
[TBL] [Abstract][Full Text] [Related]
59. Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy.
Shah DK; Shin BS; Veith J; Tóth K; Bernacki RJ; Balthasar JP
J Pharmacol Exp Ther; 2009 May; 329(2):580-91. PubMed ID: 19233938
[TBL] [Abstract][Full Text] [Related]
60. 120 peritoneal carcinomatoses from colorectal cancer treated with peritonectomy and intra-abdominal chemohyperthermia: a S.I.T.I.L.O. multicentric study.
Cavaliere F; Valle M; De Simone M; Deraco M; Rossi CR; Di Filippo F; Verzi S; Giannarelli D; Perri P; Pilati PL; Vaira M; Di Filippo S; Garofalo A
In Vivo; 2006; 20(6A):747-50. PubMed ID: 17203760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
